The newer macrolides. Azithromycin and clarithromycin. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


The newer macrolides. Azithromycin and clarithromycin.

Infect Dis Clin North Am. 1995 Sep;9(3):731-45. Unique Identifier : AIDSLINE MED/96087611
Zuckerman JM; Kaye KM; Temple University School of Medicine, Philadelphia, Pennsylvania,; USA.

Abstract: Azithromycin and clarithromycin are structural analogues of erythromycin that have similar mechanisms of action. The newer macrolides have several distinct advantages over erythromycin, including improved oral bioavailability; longer half-life, allowing once or twice daily administration; higher tissue concentrations; and fewer gastrointestinal adverse effects. Clarithromycin and azithromycin also have enhanced antimicrobial activity. The clinical efficacy of the newer macrolides has been similar to erythromycin for the treatment of upper and lower respiratory tract and skin and soft tissue infections. New therapeutic roles include the use of azithromycin for C. trachomatis infections and the inclusion of clarithromycin or azithromycin as part of therapeutic regimens for disseminated MAC infections in HIV-infected patients. Further clinical trials are needed to determine the optimal roles for and uses of these new macrolides.
Keywords: Antibiotics, Macrolide/*THERAPEUTIC USE Azithromycin/ADVERSE EFFECTS/PHARMACOLOGY/*THERAPEUTIC USE Clarithromycin/ADVERSE EFFECTS/PHARMACOLOGY/*THERAPEUTIC USE Drug Resistance, Microbial Human Respiratory Tract Infections/DRUG THERAPY JOURNAL ARTICLE REVIEW REVIEW, TUTORIALKWDantibiotics,macrolide/KWDtherapeuticuseazithromycin/adverseeffects/pharmacology/KWDtherapeuticuseclarithromycin/adverseeffects/pharmacology/KWDtherapeuticusedrugresistance,microbialhumanrespiratorytractinfections/drugtherapyjournalarticlereviewreview,tutorial
960330
M9630686

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .